Search research articles
Contact Us
Filters
Showing results (61-70 of 68) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 68 results.
Gynecologic Oncology
|
February 4, 2022
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
Fabian Trillsch, Sven Mahner, Beyhan Ataseven, et al.
Therapeutic Advances in Medical Oncology
|
September 29, 2022
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Maria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2023
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, et al.
Clinical Therapeutics
|
July 17, 2024
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Bradley J Monk, Ignacio Romero, Whitney Graybill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
Brian M Slomovitz, David Cibula, Weiguo Lv, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes
Christian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
Gynecologic Oncology
|
July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
Mark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Science (New York, N.Y.)
|
May 30, 2020
The human tumor microbiome is composed of tumor type-specific intracellular bacteria
Deborah Nejman, Ilana Livyatan, Garold Fuks, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 68) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 68 results.
Gynecologic Oncology
|
February 4, 2022
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
Fabian Trillsch, Sven Mahner, Beyhan Ataseven, et al.
Therapeutic Advances in Medical Oncology
|
September 29, 2022
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Maria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2023
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, et al.
Clinical Therapeutics
|
July 17, 2024
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Bradley J Monk, Ignacio Romero, Whitney Graybill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
Brian M Slomovitz, David Cibula, Weiguo Lv, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes
Christian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
Gynecologic Oncology
|
July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
Mark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Science (New York, N.Y.)
|
May 30, 2020
The human tumor microbiome is composed of tumor type-specific intracellular bacteria
Deborah Nejman, Ilana Livyatan, Garold Fuks, et al.
Page
of 7